Table 1 Effect of individual compounds on viability of GBM cell lines (N ≥ 4).
Compound | U-251 MG | T98-G | ||||
|---|---|---|---|---|---|---|
pIC50 [CI] | IC50, µM | Bottom plateau, % [CI] | pIC50 [CI] | IC50, µM | Bottom plateau, % [CI] | |
Temozolomide | 3.50 [3.63 to 3.37] | 317 | 0 [− 5 to 4] (ns) | 3.60 [3.73 to 3.48] | 249 | 0 [− 5 to 5] (ns) |
Lomustine | 4.50 [4.57 to 4.43] | 31.6 | 0 [− 3 to 4] (ns) | 4.08 [4.15 to 4.00] | 84.1 | 0 [− 5 to 4] (ns) |
Pasireotide | 4.02 [4.28 to 3.76] | 96.4 | 0 [− 8 to 8] (ns) | 4.00 [4.30 to 3.71] | 99.3 | 0 [− 10 to 10] (ns) |
CYN 154,806 | 3.02 [3.45 to 2.58] | 962 | 0 [− 9 to 8] (ns) | 3.44 [3.69 to 3.20] | 360 | 0 [− 10 to 9] (ns) |
MK-2206 | 5.17 [5.28 to 5.06] | 6.82 | 1 [− 4 to 6] (ns) | 4.77 [4.88 to 4.66] | 17.1 | − 6 [− 12 to 1] (ns) |
ARQ 092 | 5.06 [5.17 to 4.96] | 8.72 | − 3 [− 8 to 3] (ns) | 4.54 [4.67 to 4.42] | 28.9 | − 5 [− 13 to 2] (ns) |
ARC-775 | 4.84 [4.96 to 4.73] | 14.3 | 0 [− 8 to 9] (ns) | 4.71 [4.84 to 4.57] | 19.7 | 1 [− 9 to 10] (ns) |
CX-4945 | 5.30 [5.41 to 5.19] | 5.05 | 4 [− 5 to 11] (ns) | 5.17 [5.30 to 5.04] | 6.79 | 3 [− 7 to 12] (ns) |
SAHA | 4.83 [4.94 to 4.73] | 14.8 | − 1 [− 7 to 4] (ns) | 4.70 [4.82 to 4.59] | 20.0 | − 4 [− 11 to 2] (ns) |
Azacytidine | 5.11 [5.24 to 5.00] | 7.68 | 12 [7 to 17] (***) | 4.99 [5.12 to 4.86] | 10.3 | 6 [0 to 12] (ns) |
MK-1775 | 5.69 [5.83 to 5.55] | 2.06 | 27 [23 to 30] (***) | 6.47 [6.60 to 6.34] | 0.341 | 17 [14 to 21] (***) |
CC-115 | 6.33 [6.43 to 6.24] | 0.469 | 17 [14 to 19] (***) | 5.57 [5.69 to 5.46] | 2.68 | 16 [13 to 20] (***) |
MLN8237 | 10.0 [10.4 to 9.69] | 0.0000979 | 43 [39 to 48] (***) | 10.2 [10.7 to 9.69] | 0.0000669 | 56 [52 to 61] (***) |
VX 689 | 7.22 [7.53 to 6.93] | 0.0597 | 49 [43 to 55] (***) | 7.23 [7.59 to 6.87] | 0.0589 | 54 [47 to 61] (***) |
AZD1152-HQPA | 7.63 [7.97 to 7.30] | 0.0235 | 66 [62 to 70] (***) | 6.00 [6.40 to 5.60] | 1.01 | 67 [61 to 73] (***) |
